| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.1 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.1 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.085 | 0.1 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.087 | 0.1 |